InnoCare's Inflection Point: First Profit, Pipeline Explosion

Revenue up 55% and net profit positive as a multi-franchise biopharma emerges

9969.HK · Earnings Call · 2026-08-24

A Financial Turn

InnoCare Pharma's first-half 2026 report marks a clear inflection point. For the first time, the company generated a net profit (RMB 240 million vs. a RMB 36 million loss a year ago), on total revenue that jumped 55.5% to RMB 1.14 billion. Drug sales—the core engine—grew 43.2% to RMB 918 million. CFO Xin Fu was unapologetic: “In the first half of 2026, InnoCare delivered a very strong financial performance and continued to beat our expectations.” — Xin Fu · 2026-08-24 This is not just a one-quarter blip. The company maintains a cash position of ~RMB 8.4 billion, and management reiterated confidence in full-year profitability, with drug sales guidance of >35% growth. The beat was driven by orelabrutinib (first-line CLL/SLL inclusion in the NRDL), and the first full-year contributions from tafasitamab and zurletrectinib. As Fu noted on the call: “We are very confident to beat the 35% full year growth rate.” — Xin Fu · 2026-08-24

The Pipeline: From One Product to a Platform

What makes this quarter stand out is not just the financials—it's the breadth of late-stage and early-stage assets. The autoimmune disease franchise now has three Phase III programs (orelabrutinib in SLE, plus PPMS/SPMS with Zenas) and two TYK2 inhibitors with impressive data. In dermatology, soficitinib met its primary endpoint in atopic dermatitis and in vitiligo Phase II, while fadeucravacitinib met both co-primaries in psoriasis. The deeper story is in the early pipeline: ICP-538 (VAV1 degrader) and ICP-054 (oral IL-17) are both in Phase I and generating exciting preclinical data. As Dr. Jasmine Cui explained: “We have a lot of high hope or potential on the molecule... It is the last choice of the autoimmune disease drug.” — Jisong Cui · 2026-08-24 On the hematology side, mesutoclax (BCL-2 inhibitor) is shaping up to be a potential blockbuster. In a head-to-head vs. venetoclax in AML, it showed a composite CR rate of 81.8% and an SAE rate of only 20.5%—dramatically lower than competitors. Dr. Renbin Zhao outlined the design edge: “The molecule design for mesutoclax effectively eliminates the metabolite hotspot... demonstrating an excellent efficacy and safety profile.” — Renbin Zhao · 2026-08-24 The company has initiated a Phase III in first-line AML and is advancing pivotal programs in MCL and MZL.

Solid Tumors and the ADC Platform

The solid tumor franchise is no longer a distant promise. Zurletrectinib, a next-gen TRK inhibitor, is already commercialized, with a pediatric NDA pending. The ADC platform is the real headline: B7-H3 (ICP-B794) is in dose escalation with no DLTs, CDH17 (ICP-B208) is moving quickly, and a novel bispecific (ICP-B381, PSMA/STEAP1) is entering clinic. These assets could diversify beyond the company's hematology core.

Targeting VAV1 enables modulation of T and B cell functions, offering a new approach of treating autoimmune disorders, including some hard-to-treat indications.
Xiangyang Chen · 2026-08-24

Catalysts and Deals

Management expects multiple data readouts and regulatory submissions over the next 12–18 months: ITP NDA approval, Phase III data for orelabrutinib in CLL/SLL, and early-stage readouts for ICP-538 and ICP-054. On the business development front, Dr. Cui was measured but active, having returned from the U.S. with ongoing discussions. She emphasized that they are not in a rush to trade cash for partnerships: “We choose our partners very carefully. We are not urgent to get the cash and trade it for the cash.” — Jisong Cui · 2026-08-24 This is a company that has crossed the profitability threshold while simultaneously expanding its pipeline across three therapeutic areas. The primary endpoint successes in AD, psoriasis, and vitiligo de-risk the near-term filings. The BCL 2 inhibitor story offers a larger commercial opportunity than most investors appreciate. InnoCare is no longer a single-product story—it is a multi-franchise biopharma with genuine global potential.